

Adult Urinary Tract Infection (UTI) Guideline

Definitions

Asymptomatic Bacteriuria (ASB)	Presence of bacteriuria (defined as having urine culture with >10 ⁵ CFU/mI) in the absence of any urinary tract symptoms		
Uncomplicated Cystitis	Presence of typical lower urinary tract symptoms (dysuria, frequency, urgency, hematuria) AND lack of upper tract symptoms in an otherwise healthy pre-menopausal female		
Complicated Cystitis	Complicated: Above symptoms with any underlying condition or factors which increases risk of treatment failure Male sex Poorly controlled diabetes Pregnancy Symptoms ≥7 days prior to seeking care Hospital acquired infection Renal failure Urinary tract obstruction Presence of indwelling urethral catheter, stent, nephrostomy tube or urinary diversion Recent urinary tract instrumentation Functional or anatomic abnormality of the urinary tract Renal transplantation Immunocompromised status (e.g. chronic high dose corticosteroids ≥20mg/day of prednisone, neutropenia, advanced HIV infection) 		
Pyelonephritis	Presence of upper urinary tract symptoms such as fever, costovertebral angle (CVA) tenderness, nausea, vomiting, and signs of severe sepsis		
Catheter-Associated UTI (CA-UTI)	Patients with indwelling bladder urinary catheter through urethra > 2 days, who presents with urinary tract symptoms and a positive urine culture		

<u>Algorithm</u>



<u>Diagnosis</u>

Category	Screening Plan	Diagnosing / Interpretation
Asymptomatic Bacteriuria (ASB)	 For patients who do not have any lower or upper urinary tract symptoms do <u>NOT</u> screen unless Pregnant Undergoing transurethral resection of prostate (TURP) or any other urological procedure with risk of mucosal bleeding Renal transplant patient Neutropenic 	
Uncomplicated Cystitis	No screening required	
Complicated Cystitis	Obtain urinalysis with reflex to urine culture if patient has symptoms of UTI	 Interpretation of the Urinalysis – Positive if there is presence of Leukocyte esterase: white blood cells in the urine Bacteria: presence indicates infection WBC: >10 WBC/hpf indicates pyuria
Pyelonephritis	 Specimen collection: Sample should be collected midstream 	 Pyuria negative predictive value 96% Pyuria positive predictive value 37% Nitrite: positive indicates presence of bacteria that reduce nitrate
Catheter- Associated UTI (CA-UTI)	 Obtain urinalysis with reflex to urine culture if patient has symptoms of UTI If catheter present for >2 weeks, replace catheter prior to obtaining urine culture 	 Interpretation of the urine culture Positive cultures (non CA-UTI patients): clean catch specimen with pyuria and ≥10⁵ CFU/ml of one or more bacterial species Positive cultures (CA-UTI patients): catheterized specimen with >10³ CFU/ml of one or more bacterial species Pyuria and bacteriuria can be present due to catheter and are not an indication for treatment without symptoms Contamination: >20 squamous cells/hpf, presence of ≥3 bacterial species in urine

<u>Treatment</u>

Category	Common organisms	First-line for empiric treatment **De-escalate antimicrobial therapy after urine culture susceptibilities are available**	Alternative Agents
Uncomplicated Cystitis	E. coli	Nitrofurantoin 100mg PO BID x 5 days For patients CrCl>30ml/min	 Cephalexin 500mg PO Q12H x 5 days[#] TMP/SMX 160/800mg PO Q12H x 3 days[#]
Complicated Cystitis	<i>E. coli,</i> Klebsiella, Proteus, Other Enterobactericiae	Nitrofurantoin 100mg PO BID x 7 days For patients CrCl>30ml/min	 Cephalexin 500mg PO Q12H x 7 days[#] TMP/SMX 160/800mg PO Q12H x 7 days[#] Levofloxacin 250mg PO Q24H x 5 days[#]
Pyelonephritis	 <i>E. coli,</i> Klebsiella, Serratia, Citrobacter, Other Enterobactericiae <i>P. aeruginosa</i> Enterococcus 	 Outpatient: Ciprofloxacin 500mg PO BID x 7 days[#] Inpatient-Community acquired: Ceftriaxone 1g IV daily Inpatient-Hospital acquired Piperacillin/tazobactam 3.375g IV Q6H[#] Inpatient-History of ESBL infection: Meropenem 1g IV Q8H[#] Amikacin 15 mg/kg IV Q24H^{#¶} Duration: 7-14 days Use the shortest duration (7 days) if patient is clinically improving 	Inpatient-Community acquired: <u>Penicillin allergy (IgE-mediated)</u> : • Gentamicin 5mg/kg IV Q24H ^{#¶} <u>Penicillin allergy + acute renal failure</u> : • Levofloxacin 500mg IV daily [#] Inpatient-Hospital acquired <u>Penicillin allergy (Not IgE-mediated)</u> : • Cefepime 1g IV Q8H [#] <u>Penicillin allergy (IgE-mediated)</u> : • Gentamicin 5mg/kg IV Q24H ^{#¶} <u>Penicillin allergy + acute renal failure</u> : • Levofloxacin 500mg IV daily [#] Duration: 7-14 days Use the shortest duration (7 days) if patient is clinically improving
CA-UTI	 <i>E. coli,</i> Klebsiella, Serratia, Citrobacter, Enterobacter <i>P. aeruginosa</i> Gram positive cocci (including coagulase negative staphylococci) Enterococcus species 	 Removal of urinary catheter if possible Antibiotic treatment same as pyelonephritis 	 Removal of urinary catheter if possible Antibiotic treatment same as pyelonephritis

Pregnancy	 <i>E. coli</i> Group B streptococcus, <i>Staphylococcus saprophyticus</i> Klebsiella, Enterobacter Enterococcus 	 Asymptomatic bacteriuria or acute cystitis: Amoxicillin 500mg PO Q8H# Cephalexin 500mg PO Q12H# Duration: 3-7 days Pyelonephritis: Ceftriaxone 1g IV Q24H Duration: 7-14 days Use the shortest duration (7 days) if patient is clinically improving 	 Asymptomatic bacteriuria or acute cystitis: TMP/SMX 160/800mg PO Q12H x 3 days (avoid in 1st and 3rd trimester)[#] Nitrofurantoin 100mg PO Q12H x 5 days (avoid in 1st and 3rd trimester) Pyelonephritis: Gentamicin 5mg/kg IV Q24H^{#1} Duration: 7-14 days Use the shortest duration (7 days) if patient is clinically 			
	linto uno stieve including encohulouis unticou	ial angiandama chartraca of brooth ata	improving			
ige-mediated = immediate reactions including anaphylaxis, urticarial, angioedema, shortness of breath, etc						
t = requires renal dose adjustment						
¶ = dose based on ideal body weight. For obese patients, use adjusted body weight						

References

Dull RB, Friedman SK, Risoldi ZM, et al. Antimicrobial treatment of asymptomatic bacteriuria in noncatheterized adults: a systematic review. Pharmacotherapy. 2014;34(9):941-60.

Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011 Mar 1;52(5):e103-20.

Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:625-63

Nicolle LE, Bradley S, Colgan R, et al. Infectious diseases society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005;40:643-54.

Trautner BW, Grigoryan L, Petersen NJ, et al. Effectiveness of an antimicrobial stewardship approach for urinary catheter-associated asymptomatic bacteriuria. JAMA Intern Med. 2015;175(7):1120-2.